- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Intelligent Bio Solutions GAAP EPS of -$8.44, revenue of $4.22M | 3 | Seeking Alpha | ||
| Mi | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Mi | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth | 145 | GlobeNewswire (Europe) | Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year... ► Artikel lesen | |
| Mi | INTELLIGENT BIO SOLUTIONS INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 17.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification | 172 | GlobeNewswire (Europe) | NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 11.08. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 5 | SEC Filings | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 11.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System | 4 | GlobeNewswire (USA) | ||
| 05.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission | 165 | GlobeNewswire (Europe) | NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 03.08. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System | 259 | GlobeNewswire (Europe) | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 23.07. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry | 265 | GlobeNewswire (Europe) | Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation 510(k) package submission on track for calendar H2 2026, targeting planned... ► Artikel lesen | |
| 21.07. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market | 265 | GlobeNewswire (Europe) | NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 16.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.06. | Intelligent Bio Solutions starts interference study for FDA submission | 1 | Investing.com | ||
| 16.06. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | 287 | GlobeNewswire (Europe) | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| 02.06. | Intelligent Bio Solutions starts FDA study for fingerprint drug test | 2 | Investing.com | ||
| 02.06. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.05. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year | 244 | GlobeNewswire (Europe) | Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07 million, up 39% year-over-year, building... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,650 | +1,26 % | Eckert & Ziegler: Strahlkraft der Radiopharmaka revolutioniert den Gesundheitssektor | ||
| DRAEGERWERK | 110,80 | +0,36 % | dpa-AFX-Überblick: UNTERNEHMEN vom 10.08.2026 - 15.15 Uhr | ROUNDUP: Hypoport bestätigt Jahresziele für 2026 - Aktie legt zu BERLIN - Der Finanzdienstleister Hypoport sieht sich auf Kurs zu seinen Jahreszielen. "Die geopolitischen Spannungen des ersten Halbjahres... ► Artikel lesen | |
| TELADOC HEALTH | 5,512 | +0,66 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| HIMS & HERS HEALTH | 28,960 | +0,07 % | Hims & Hers Health facing penalties from Visa for credit card disputes - report | ||
| BICO GROUP | 1,788 | -0,22 % | BICO Group AB: Publication of BICO Group AB: Interim Report Q2 2026 | Improved profitability and AI advancements
"In the quarter we had a continued solid momentum with growth in our bench top instruments and consumables businesses, while still experiencing challenges... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,069 | +1,46 % | Sernova Biotherapeutics, Inc.: Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy | TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova" or the "Company") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,640 | +2,33 % | Dividendenbekanntmachungen (27.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ATHOS IMMOBILIEN AG AT0000616701 - 0,8 EUR FVCBANKCORP INC US36120Q1013 0,07 USD 0,0615 EUR GAS PLUS SPA IT0004098510 - 0,25 EUR GERATHERM... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 137,60 | -1,15 % | Align Technology Wins China Patent Case Against Angelalign | WASHINGTON (dpa-AFX) - Align Technology, Inc. (ALGN), said the Jinan Intermediate People's Court in China ruled in its favor in a patent infringement case against Angelalign Technology's Chinese... ► Artikel lesen | |
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
10.08.2026 / 09:00 CET/CEST
The... ► Artikel lesen | |
| CERENOME | 2,555 | 0,00 % | Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook | ||
| NUGEN MEDICAL DEVICES | 0,011 | 0,00 % | XFRA 79O: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUGEN MEDICAL DEV.... ► Artikel lesen | |
| HEALWELL AI | 0,487 | -0,81 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,200 | +1,85 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| INVITAE | - | - | Patentstreit: Natera sichert sich 30 % Lizenzgebühr von Invitae | ||
| SPINEWAY | 0,121 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen |
INTELLIGENT BIO SOLUTIONS INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,020 (+0,80 %) liegt der Kurs bei 2,530 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTELLIGENT BIO SOLUTIONS INC finden Sie auf Wallstreet Online.